FDA Sends 30 Warning Letters To Continue Clampdown on Compounded GLP 1s BioSpace FDA Warning Letter Breakdown: Sterility Failures, Subpotent GLP 1 Drugs, and a Compounding Pharmacy Operating Without Control FDA Issues Warning: Compounding Certain Bulk Drug Substances May Pose Major Legal and Patient Safety Risks Lengea Content Analysis of US FDA Warning Letters Issued to Compounding Pharmacies Regarding Violations of Current Good Manufacturing Practices Between 2017 and 2022 Journal of Pharmaceutical Innovation Springer Nature Link The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide